PMID- 37954087
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231114
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a 
      meta-analysis.
PG  - 1245650
LID - 10.3389/fonc.2023.1245650 [doi]
LID - 1245650
AB  - INTRODUCTION: The efficacy and safety of adjuvant capecitabine in early-stage 
      triple-negative breast cancer remains undefined. A meta-analysis was conducted to 
      elucidate whether capecitabine-based regimens could improve survival in 
      early-stage triple-negative breast cancer (TNBC). METHODS: The current study 
      searched Medline, Embase, Cochrane Library, Web of Science, and 
      ClinicalTrials.gov proceedings up to 2023.9. Disease-free survival (DFS), overall 
      survival (OS), and grade 3-4 adverse events (AEs) were assessed. Extracted or 
      calculated hazard ratios (HRs) and odds ratios (ORs) with 95% confidence 
      intervals (CIs) were pooled. RESULTS: The capecitabine-based regimens showed 
      significant advantages in DFS (HR = 0.81, 95% CI: 0.73-0.90; P <.001) and OS (HR 
      = 0.75, 95% CI: 0.65-0.87; P <.001) from 12 randomized controlled trials (RCTs) 
      with 5,390 unselected participants. Subgroup analysis of DFS showed analogous 
      results derived from patients with lymph node negative (HR = 0.68, 95% CI: 
      0.50-0.92; P = .006) and capecitabine duration no less than six cycles (HR = 
      0.73; 95% CI: 0.62-0.86; P <.001). Improvement of DFS in the addition group (HR = 
      0.77, 95% CI: 0.68-0.87; P <.001) and adjuvant setting (HR = 0.79, 95% CI: 
      0.70-0.89; P <.001) was observed. As to safety profile, capecitabine was 
      associated with more frequent stomatitis (OR = 5.05, 95% CI: 1.45-17.65, P = 
      .011), diarrhea (OR = 6.11, 95% CI: 2.12-17.56; P =.001), and hand-foot syndrome 
      (OR = 31.82, 95% CI: 3.23-313.65, P = .003). CONCLUSIONS: Adjuvant 
      capecitabine-based chemotherapy provided superior DFS and OS to early-stage TNBC. 
      The benefits to DFS in selected patients with lymph node negative and the 
      addition and extended duration of capecitabine were demonstrated.
CI  - Copyright (c) 2023 Bai, Yao, Pu, Wang and Luo.
FAU - Bai, Jie
AU  - Bai J
AD  - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing, China.
FAU - Yao, Xufeng
AU  - Yao X
AD  - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing, China.
AD  - Department of Head and Neck Surgery, The First Hospital of Jiaxing, Zhejiang, 
      China.
FAU - Pu, Yinghong
AU  - Pu Y
AD  - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing, China.
FAU - Wang, Xiaoyi
AU  - Wang X
AD  - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing, China.
FAU - Luo, Xinrong
AU  - Luo X
AD  - Department of Breast and Thyroid Surgery, The First Affiliated Hospital of 
      Chongqing Medical University, Chongqing, China.
LA  - eng
PT  - Systematic Review
DEP - 20231025
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10634425
OTO - NOTNLM
OT  - adverse events
OT  - capecitabine
OT  - chemotherapy
OT  - survival
OT  - triple-negative breast cancer
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/11/13 06:43
MHDA- 2023/11/13 06:44
PMCR- 2023/01/01
CRDT- 2023/11/13 04:24
PHST- 2023/06/23 00:00 [received]
PHST- 2023/10/03 00:00 [accepted]
PHST- 2023/11/13 06:44 [medline]
PHST- 2023/11/13 06:43 [pubmed]
PHST- 2023/11/13 04:24 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1245650 [doi]
PST - epublish
SO  - Front Oncol. 2023 Oct 25;13:1245650. doi: 10.3389/fonc.2023.1245650. eCollection 
      2023.